<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7145592</article-id>
    <article-id pub-id-type="pmid">31642488</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkz917</article-id>
    <article-id pub-id-type="publisher-id">gkz917</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ExonSkipDB: functional annotation of exon skipping event in human</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Kim</surname>
          <given-names>Pora</given-names>
        </name>
        <!--<email>Pora.Kim@uth.tmc.edu</email>-->
        <xref ref-type="aff" rid="AFF1">1</xref>
        <xref ref-type="author-notes" rid="FN1"/>
        <xref ref-type="corresp" rid="COR2"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Mengyuan</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">1</xref>
        <xref ref-type="author-notes" rid="FN1"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yiya</surname>
          <given-names>Ke</given-names>
        </name>
        <xref ref-type="aff" rid="AFF2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhao</surname>
          <given-names>Weiling</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhou</surname>
          <given-names>Xiaobo</given-names>
        </name>
        <!--<email>Xiaobo.Zhou@uth.tmc.edu</email>-->
        <xref ref-type="aff" rid="AFF1">1</xref>
        <xref ref-type="aff" rid="AFF3">3</xref>
        <xref ref-type="aff" rid="AFF4">4</xref>
        <xref ref-type="corresp" rid="COR1"/>
      </contrib>
    </contrib-group>
    <aff id="AFF1"><label>1</label><institution>School of Biomedical Informatics, The University of Texas Health Science Center at Houston</institution>, Houston, TX 77030, <country country="US">USA</country></aff>
    <aff id="AFF2"><label>2</label><institution>College of Electronics and Information Engineering, Tongji University</institution>, Shanghai, <country country="CN">China</country></aff>
    <aff id="AFF3"><label>3</label><institution>McGovern Medical School, The University of Texas Health Science Center at Houston</institution>, Houston, TX 77030, <country country="US">USA</country></aff>
    <aff id="AFF4"><label>4</label><institution>School of Dentistry, The University of Texas Health Science Center at Houston</institution>, Houston, TX 77030, <country country="US">USA</country></aff>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +1 713 500 3923; Email: <email>Xiaobo.Zhou@uth.tmc.edu</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Pora Kim. Tel: +1 713 500 3636; Email: <email>Pora.Kim@uth.tmc.edu</email></corresp>
      <fn id="FN1">
        <p>These authors contributed equally to this work.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="ppub">
      <day>08</day>
      <month>1</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2019-10-23">
      <day>23</day>
      <month>10</month>
      <year>2019</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>23</day>
      <month>10</month>
      <year>2019</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
    <volume>48</volume>
    <issue>D1</issue>
    <fpage>D896</fpage>
    <lpage>D907</lpage>
    <history>
      <date date-type="accepted">
        <day>03</day>
        <month>10</month>
        <year>2019</year>
      </date>
      <date date-type="rev-recd">
        <day>21</day>
        <month>9</month>
        <year>2019</year>
      </date>
      <date date-type="received">
        <day>13</day>
        <month>8</month>
        <year>2019</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2019. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2019</copyright-year>
      <license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkz917.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Exon skipping (ES) is reported to be the most common alternative splicing event due to loss of functional domains/sites or shifting of the open reading frame (ORF), leading to a variety of human diseases and considered therapeutic targets. To date, systematic and intensive annotations of ES events based on the skipped exon units in cancer and normal tissues are not available. Here, we built ExonSkipDB, the ES annotation database available at <ext-link ext-link-type="uri" xlink:href="https://ccsm.uth.edu/ExonSkipDB/">https://ccsm.uth.edu/ExonSkipDB/</ext-link>, aiming to provide a resource and reference for functional annotation of ES events in multiple cancer and tissues to identify therapeutically targetable genes in individual exon units. We collected 14 272 genes that have 90 616 and 89 845 ES events across 33 cancer types and 31 normal tissues from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx). For the ES events, we performed multiple functional annotations. These include ORF assignment of exon skipped transcript, studies of lost protein functional features due to ES events, and studies of exon skipping events associated with mutations and methylations based on multi-omics evidence. ExonSkipDB will be a unique resource for cancer and drug research communities to identify therapeutically targetable exon skipping events.</p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <named-content content-type="funder-name">National Institutes of Health</named-content>
          <named-content content-type="funder-identifier">10.13039/100000002</named-content>
        </funding-source>
        <award-id>R01GM123037</award-id>
        <award-id>U01AR069395-01A1</award-id>
        <award-id>R01CA241930</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="12"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>Accumulated evidence has shown that the disruption of alternative splicing (AS) contributes to human diseases (<xref rid="B1" ref-type="bibr">1</xref>). Among the typical patterns of alternative splicing, exon skipping (ES) is the most common event (<xref rid="B2" ref-type="bibr">2</xref>). Since ES results in the loss of functional domains/sites or frame shifting of the open reading frame (ORF), skipped exons have been used as therapeutic targets (<xref rid="B3" ref-type="bibr">3–8</xref>). For example, <italic>MET</italic> has lost the binding site of E3 ubiquitin ligase CBL through exon 14 skipping event (<xref rid="B9" ref-type="bibr">9</xref>), resulting in an enhanced expression level of <italic>MET</italic>. <italic>MET</italic> amplification drives the proliferation of tumor cells. Multiple tyrosine kinase inhibitors, such as crizotinib, cabozantinib and capmatinib, have been used to treat patients with <italic>MET</italic> exon 14 skipping (<xref rid="B10" ref-type="bibr">10</xref>). Another example is the dystrophin gene (<italic>DMD</italic>) in Duchenne muscular dystrophy (DMD), a progressive neuromuscular disorder. To restore dystrophin protein functions that were lost due to frame shifting through ES, multi-exon skipping antisense oligonucleotides (ASOs) have been used for <italic>DMD</italic> treatment (<xref rid="B11" ref-type="bibr">11</xref>). Therefore, systematic identification and intensive analyses of ES events in pan-cancer and healthy tissues will provide important insights into disease mechanisms and identify novel cancer type-specific therapeutic targets.</p>
    <p>With the recent exponential growth of cancer genomic and other biomedical data, several studies have analyzed alternative splicing events in multiple cancer or tissue types (e.g. pan-cancer studies) (<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>). There exist several web tools providing pan-cancer AS annotations such as TCGA SpliceSeq (<xref rid="B14" ref-type="bibr">14</xref>), TSVdb (<xref rid="B15" ref-type="bibr">15</xref>) and CAS-viewer (<xref rid="B16" ref-type="bibr">16</xref>). However, these studies focused on the identification of alternative splicing events and visualization of isoform structures based on known gene structures. Furthermore, these studies did not present detailed functional impacts of AS events. So far, a systematic and intensive annotation of ES events based on the skipped exon units in cancer and normal tissues regarding their functional impacts has not been available. Here, we built ExonSkipDB, the ES annotation database, aiming to provide resources and references for functional annotation of ES events in cancer to identify therapeutically targetable exons.</p>
    <p>To achieve this goal, we first collected ES event information of total 14 272 genes from 33 cancer types and 31 normal tissues of the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) from Kahles <italic>et al.</italic>’s study (<xref rid="B12" ref-type="bibr">12</xref>). These genes contain 90 616 and 89 845 ES events of TCGA and GTEx, respectively. For these ∼14K genes, we performed functional annotations including investigation of the open reading frame (ORF) for individual ES events and lost protein functional features of in-frame ES events based-on the canonical transcript sequences and amino acid sequences, respectively. We also analyzed mutations and methylations associated with ES events. Users can access a variety of annotations, including gene summaries, gene structures such as gene isoform and ES events from TCGA and GTEx, landscape of percent spliced in (PSI) and isoform abundances across multiple human tissues and cancers, ORF annotation, analysis of lost protein functional features, skipped exon region mutations with coverage depth and differential PSIs, sQTL and sQTM analyses, and ES gene-related drugs and diseases. This paper introduces ExonSkipDB, the web interface, and its applications, aiming to provide resources or references for functional annotation of exon skipping events in cancer. ExonSkipDB will be a unique resource for cancer and drug research communities to identify disease-associated exon skipping events.</p>
  </sec>
  <sec id="SEC2">
    <title>DATABASE OVERVIEW</title>
    <p>Through multiple annotations of the ExonSkipDB, users can get help from the following aspects. (i) Comparing ES events with PSIs and isoform abundance between pan-cancer and healthy human tissues can help detect potential cancer or cancer type-specific ES events. Through comparing 90 616 and 89 845 ES events from TCGA and GTEx, we identified 121 cancer-specific in-frame ES events-related genes. (ii) Analysis of the lost protein features of exon skipping events will help to deepen understanding the detailed loss-of-functional effects of tumorigenic ES events. We have identified 2427 and 249 in-frame genes that have lost protein functional domains and DNA-binding domain, respectively. One hundred forty-two genes lost specific amino acid sites such as the site required for ligand-induced CBL-mediated ubiquitination in <italic>MET</italic> exon 14. (iii) ORF annotation of skipped exons classifies translational and non-translational ES events and provides potential candidates to be targeted by antisense oligonucleotides to restore lost protein functions. Among ∼14 000 genes with ES events in cancer, there were 8667 and 9623 ES genes of in-frame and frame-shift ORFs, respectively. Among 9623 genes with the frame-shifted ES events, 453 genes can be targeted by the drugs from IUPHAR database. (iv) RNA-seq data studies, such as coverage depth check, differences in PSI value between mutated and non-mutated samples, and split read abundance evidence by sashimi plots, can identify mutation-associated ES events. One hundred twenty-three genes with non-synonymous mutations around skipped exons showed decreased expression at the skipped exons with differential PSI values compared to non-mutated samples of same cancer type. Furthermore, we performed manual curation of PubMed articles for 711 genes with recurrent splice-site or nonsense mutations. (v) Based on the involvement of methylation in differentiating elongation rate of Pol II (<xref rid="B17" ref-type="bibr">17</xref>), we analyzed the association between splicing and methylation (ES-specific splicing Quantitative Trait Methylation, sQTM). Through systematic survival analysis of sQTM pairs, we identified 50 prognostic cases. In addition, we identified 1534 approved drugs for targeting 1715 ES genes, and 7324 genes reported to be associated with 5039 different types of diseases in DrugBank (<xref rid="B18" ref-type="bibr">18</xref>) and DisGeNet (<xref rid="B19" ref-type="bibr">19</xref>), respectively. Figure <xref ref-type="fig" rid="F1">1</xref> is an overview of ES annotations using MET as a representative example. All entries and annotation data are available for browsing and downloading on the ExonSkipDB web site (<ext-link ext-link-type="uri" xlink:href="https://ccsm.uth.edu/ExonSkipDB">https://ccsm.uth.edu/ExonSkipDB</ext-link>).</p>
    <fig id="F1" orientation="portrait" position="float">
      <label>Figure 1.</label>
      <caption>
        <p>Overview of ExonSkipDB. (<bold>A</bold>) The genomic structures of exon skipping events of TCGA and GTEx across reference gene model. (<bold>B</bold>) Abundance of isoforms and PSI values of individual exon skipping events across TCGA and GTEx. (<bold>C</bold>) The protein functional features based on the canonical protein sequence. The grey color shaded regions correspond to individual exon skipping events. (<bold>D</bold>) The analyzed ORF information of individual exon skipping events based on the canonical transcript sequence. (<bold>E</bold>) RNA-seq evidence for the mutation-associated exon skipping event. Consistent evidence through the depth of coverage, differential PSI values between mutated and non-mutated samples, and sashimi plots have identified 136 exon skipping events that have associations with mutations.</p>
      </caption>
      <graphic xlink:href="gkz917fig1"/>
    </fig>
  </sec>
  <sec id="SEC3">
    <title>DATA INTEGRATION AND ANNOTATIONS</title>
    <sec id="SEC3-1">
      <title>Exon skipping information</title>
      <p>We downloaded the exon skipping event information of 8,705 patients of TCGA’s 33 cancer types and over 3,000 normal samples from GTEx's 31 different tissues (<xref ref-type="supplementary-material" rid="sup1">Supplementary Tables S1 and S2</xref>) from Kahles <italic>et al.</italic>’s study (<xref rid="B12" ref-type="bibr">12</xref>). Only the exon skipping events with conserved loci among the six splice-sites of three exons were used in this study. These exons are involved in exon skipping such as ‘upstream exon’, ‘skipped exon’ and ‘downstream exon’. Of these six sites, four sites are the acceptor site of the upstream exon, the acceptor and donor sites of the skipped exon, and the donor site of the downstream exon. Based on the GENCODE v19 annotation reference genome (<xref rid="B20" ref-type="bibr">20</xref>), we obtained 90 616 and 89 845 annotated gene structure-based exon skipping events from TCGA and GTEx, respectively.</p>
    </sec>
    <sec id="SEC3-2">
      <title>Open reading frame (ORF) annotation</title>
      <p>For specific exon skipping events based on the GENCODE v19 (<xref rid="B20" ref-type="bibr">20</xref>) (<xref ref-type="supplementary-material" rid="sup1">Supplementary Tables S3 and S4</xref>), we examined the open reading frames of major isoform transcript sequences. When both of the nucleotide start and end positions of exon skipping were located inside of the coding region (CDS) and the number of transcript sequences after exclusion of the skipped exon sequence was a multiple of three, then we reported such exon skipped gene isoform as ‘in-frame’. When one or two nucleotide insertions are present, we reported such transcripts as ‘frame-shift’.</p>
    </sec>
    <sec id="SEC3-3">
      <title>Retention analysis of 39 protein features from UniProt</title>
      <p>Firstly, we created the exon skipped transcript sequence based on the canonical transcript sequence. Then this sequence was aligned with non-redundant protein sequence database using BLASTX (<xref rid="B21" ref-type="bibr">21</xref>) and the mapped proteins with 100 percent identify were selected. Through this process, we obtained the loci of skipped exon on the genomic, transcriptomic, and protein sequences for the ES genes of TCGA and GTEx (<xref ref-type="supplementary-material" rid="sup1">Supplementary Tables S5 and S6</xref>). We searched the retention of 39 protein features of UniProt (<xref rid="B22" ref-type="bibr">22</xref>) at the canonical amino acid sequence level with skipped exon loci information, including 6 molecule processing features, 13 region features, 4 site features, 6 amino acid modification features, 2 natural variation features, 5 experimental info features and 3 secondary structure features. The lost protein functional features due to ES are listed in <xref ref-type="supplementary-material" rid="sup1">Supplementary Tables S7 and S8</xref>. Detailed information about all of the protein features is in UniProt.</p>
    </sec>
    <sec id="SEC3-4">
      <title>Identifying mutations associated with exon skipping events</title>
      <p>According to Wimmer <italic>et al.</italic> and Anna and Monika (<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref>), there are five types of splicing mutations. Among these, exonic mutations creating new splicing site or leading splicing enhancer (ESE) disruption, and canonical splice site at the exon-intron boundaries can effect in improper splicing and exon skipping event. On the other hands, intronic mutations in the branch point or polypyrimidine tract, or new intronic splice site mutations can lead exon skipping or include intron fragment. In our annotation, we only could use exonic mutations since the variants of TCGA are not based on whole genome sequencing, but based on whole exon sequencing data sets. So, we tried to identify exonic mutations inducing exon skipping event including splice site mutations. For other types of exonic non-synonymous mutations, we delved into and searched for relevant publications to determine which coding region mutations may influence or induce exon skipping events. We have collected evidence of ES-induced mutations, including not only splice site mutations, but also nonsense and frameshift indel mutations from the previous studies (<xref rid="B25" ref-type="bibr">25–27</xref>; see <xref rid="B3" ref-type="bibr">3</xref>–<xref rid="B5" ref-type="bibr">5</xref>). Therefore, to identify candidate mutations that might induce the exon skipping events, we overlapped the genomic coordinates of skipped exons with three types of non-synonymous mutations, including splice-site, nonsense, and frame-shift mutations from TCGA (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S9</xref>). Using genomeCoverageBed of bedtools (<xref rid="B28" ref-type="bibr">28</xref>), we drew the coverage depth plots based on the transcript nucleotide sequences of the three exons involved in exon skipping events from the bam files of RNA-seq data of TCGA samples. If the difference of mean read count between the middle exon (alternatively spliced, skipped exon) and two neighbor exons (constitutively spliced exon) is great than 10.0, we remained these cases for next step. It resulted 3554 exon skipping events among 2402 genes in 1886 samples. Next, we chose the cases where the PSI values in the mutated samples are different from the ones in the non-mutated samples as the final candidates. Since there are not many recurrent ES events, we applied the average PSI value as the threshold. If the PSIs of the mutated sample is less than 0.3 and the PSI of the non-mutated sample is &gt;0.7, then we selected those ES events as potential mutation-associated ES events. Finally, we obtained 136 ES events from 123 genes that presented differences in coverage depth and PSIs between non-mutated and mutated samples (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S10</xref>). For these cases, we also provided sashimi plots to show additional evidence from the quantified split reads across ∼3000 cancer samples (<xref rid="B29" ref-type="bibr">29</xref>).</p>
    </sec>
    <sec id="SEC3-5">
      <title>Exon skipping specific splicing quantitative trait loci (sQTL) and methylation (sQTM) analysis</title>
      <p>For the ES-specific sQTL, we adopted sQTL analysis results from TCGA (<xref rid="B12" ref-type="bibr">12</xref>). There were 901 167 possible sQTL candidate single-nucleotide polymorphisms (SNPs) in 9909 genes across 33 cancer types. By integrating these loci with the coordinates of skipped exons, 4124 SNPs from 2254 ES genes were identified. For ES specific sQTM analysis, we first selected 2750 exon skipping events. These events have PSI values between 0.1 and 0.9 in at least 10 samples across 8088 pan-cancer samples and have methylation data in the same samples. The Illumina Human Methylation 450 data of these samples across 32 cancer types were downloaded from TCGA. Typically, a beta value greater than or equal to 0.6 is considered to be fully methylated, and a beta value less than or equal to 0.2 is considered to be fully unmethylated. Therefore, to calculate the association with PSI values, we have used the beta values between 0.2 and 0.6. We calculated the beta value for the region between the first exon's start site and the middle exon's end site. The average beta value of 1231 upstream CpG regions for individual exon skipping events in pan-cancer (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S11</xref>) was obtained. For the 8088 samples with methylation data, we investigated the effect of DNA methylation on exon skipping events using a linear regression approach, ultra-fast eQTL analysis via large matrix operations (MatrixEQTL) (<xref rid="B30" ref-type="bibr">30</xref>). We calculated the correlation <italic>p</italic>-value between the exon skipping event and its upstream region methylation, and the pair with a <italic>p</italic>-value less than 1.0 × E−5 were selected as a <italic>cis</italic>-sQTM pair. To identify the pathogenic sQTM, we performed the same analysis per cancer type and chose significant cis-sQTM pairs. For these significant <italic>cis</italic>-sQTMs, we performed the survival analysis using the survival package in R for the Kaplan–Meier method and log-rank test (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S12</xref>).</p>
    </sec>
    <sec id="SEC3-6">
      <title>Drug and disease information</title>
      <p>Drug-target interactions (DTIs) were extracted from DrugBank (<xref rid="B18" ref-type="bibr">18</xref>) (April 2018, version 5.1.0) and duplicated DTI pairs were excluded. All drugs were grouped using Anatomical Therapeutic Chemical (ATC) classification system codes. Disease-genetic information was extracted from a database of gene-disease associations (DisGeNet, June 2018, version 4.0) (<xref rid="B19" ref-type="bibr">19</xref>).</p>
    </sec>
    <sec id="SEC3-7">
      <title>Manual curation of PubMed articles</title>
      <p>For the 711 genes with recurrent splice-sites or nonsense mutations in more than two samples, PubMed's literature query was performed on June 2019 using the search expression applied to each gene. Taking <italic>MET</italic> as an example, it is ‘((<italic>MET</italic> [Title/Abstract]) AND <italic>exon</italic> [Title/Abstract]) AND skip [Title/Abstract])’. After a manual review of the abstracts, we found that there was 46 documentary evidence supporting exon skipping events of 9 genes (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S13</xref>).</p>
    </sec>
    <sec id="SEC3-8">
      <title>Database architecture</title>
      <p>The ExonSkipDB system is based on a three-tier architecture: client, server, and database. It includes a user-friendly web interface, a Perl's DBI module, and a MySQL database. This database was developed in MySQL 3.23 with the MyISAM storage engine.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC4">
    <title>WEB INTERFACE AND ANALYSIS RESULTS</title>
    <sec id="SEC4-1">
      <title>ES event gene structure browser and ES event heatmaps provide potential disease-specific ES events</title>
      <p>In order to understand the landscape of exon skipping events, co-localization information with known gene isoform structures is essential. For this, we mapped ES events based on gene structure using the custom track of UCSC genome browser (<xref rid="B31" ref-type="bibr">31</xref>). An example image of <italic>MET</italic> with the gene isoforms and skipped exons based on RefGene (<xref rid="B32" ref-type="bibr">32</xref>) and Ensembl (<xref rid="B33" ref-type="bibr">33</xref>) gene models is shown in Figure <xref ref-type="fig" rid="F1">1A</xref>. Through this image, the relationship between known isoforms and exon skipping events can be easily understood by users. In addition, the landscape of gene isoform abundance and PSI values across TCGA cancers and GTEx tissues in the heat maps allow users to gain insight into the disease- or tissue-specific exon skipping events (Figure <xref ref-type="fig" rid="F1">1B</xref>). For example, <italic>MET</italic> has three cancer-specific exon skipping events, such as ‘exon_skip_470675’, ‘exon_skip_470679’ and ‘exon_skip_470684’._In addition to ‘exon_skip_470679’, other ES events are predicted to be in-frame events based on the canonical transcript sequence (ENST00000397752). The ‘exon_skip_470675’ is located from 400 to 464 of the canonical protein amino acid sequence (P08581). From the lost protein feature analysis image in Figure <xref ref-type="fig" rid="F1">1C</xref>, this exon skipping event might lose the sema domain (PROSITE-ProRule: PRU00352 (<xref rid="B34" ref-type="bibr">34</xref>)). On the other hand, ‘exon_skip_470684’, anticipated to be located between 1009 to 1086 of the canonical amino acids, might lose protein kinase domain (PROSITE-ProRule: PRU00159) and the breakpoint for translocation to form TPR-MET oncogene. Furthermore, by comparing the ES genes with in-frame ORF between TCGA and GTEx, 121 cancer-specific ES genes were identified. Among the 121 genes, there were one of the cancer gene census genes, three kinases, four transcription factors, two tumor suppressors, and 14 IUPHAR drug targets (<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S1</xref>), including <italic>ARG2</italic>, <italic>AQP6</italic>, <italic>CDC6</italic>, <italic>DUSP9</italic>, <italic>ENPEP</italic>, <italic>GABPA</italic>, <italic>GABRA3</italic>, <italic>GPRC6A</italic>, <italic>GRM7</italic>, <italic>HTR3A</italic>, <italic>KCNU1</italic>, <italic>KLF12</italic>, <italic>NEK2</italic>, <italic>NR6A1</italic>, <italic>QRFPR</italic>, <italic>RET</italic>, <italic>SLC6A19</italic>, <italic>SLC6A3</italic>, <italic>STK17A</italic>, and <italic>TMPRSS11A</italic>. For each of these genes, the users can obtain a detailed annotation of exon skipping events (<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S2</xref>). As shown here, the gene structure images and other annotations of ExonSkipDB will help users identify disease-specific exon skipping events.</p>
    </sec>
    <sec id="SEC4-2">
      <title>ORF analysis of individual exon skipping events will be helpful for screening potential therapeutic candidates</title>
      <p>The open reading frame of the skipped exons is very important for assessing the translation capabilities of individual exon skipped transcripts into the effective proteins. We annotated the ORFs of individual ES events based on GENCODE v19. Out of 14 272 genes with ES events, we identified 8667 and 9623 genes with in-frame and frame-shift ORFs, respectively. Among the 9623 genes with frame-shifted ES events, 453 genes can be pharmacologically targeted according to the information from IUPHAR database. By performing over-representation analysis using Gene Set Enrichment Analysis (GSEA) (<xref rid="B35" ref-type="bibr">35</xref>), we found that the 181 and 173 genes are involved in ‘ion transport’ and ‘transmembrane transport’ biological pathways, respectively (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S14</xref>). These transcripts with frame-shifted ES events cannot be translated into normal proteins. If a critical functional domain is lost or partially expressed due to this frame-shift and causes disease, then we can consider the use of antisense oligonucleotide-based therapy to restore the lost function as seen in the exon skipping therapy for Duchenne muscular dystrophy (DMD) (<xref rid="B36" ref-type="bibr">36</xref>). For the genes with the in-frame ORF ES events, we systematically studied the retention of protein functional features. For example, <italic>MET</italic> has eight exon skipping events. We aligned these events on the Ensembl gene model of ENST00000397752 (Figure <xref ref-type="fig" rid="F1">1D</xref>). Among these, three and four were annotated as in-frame and frame-shift ORF ES events, respectively. As shown in Figure <xref ref-type="fig" rid="F1">1C</xref>, the transcripts with in-frame ES event can be translated into proteins; however, some functional features of these proteins will be lost. Obviously, ExonSkipDB’s ORF annotation will be helpful for users to identify translational ES events and targetable ES events for the antisense oligonucleotides (AS)s treatment.</p>
    </sec>
    <sec id="SEC4-3">
      <title>Lost protein functional features might be caused by ES events</title>
      <p>As mentioned above, the lost protein features of ES events are important for evaluating the functional effects of the related genes on tumorigenesis or disease development. Figure <xref ref-type="fig" rid="F1">1C</xref> shows an annotation of the lost protein functional features for the skipped exons of <italic>MET</italic> in the known transcripts and all in-frame ES events based on the canonical protein sequence. Through translating individual ES events at the amino acid sequence level and localizing all the protein functional features of UniProt, the users can obtain a positional relationship of the ES events and functional features. For example, <italic>MET</italic> has four in-frame ES events, which are shaded with grey in the protein feature image. Three of the four are skipped exons and one is a missed exon in the known gene isoform structure. Specifically, MET has a unique tumorigenesis site called ‘Required for ligand-induced CBL-mediated ubiquitination’. As shown in this example, the users can identify lost protein functional features of ES genes of interest.</p>
      <p>The overall statistics of all lost protein functional features of the 14 272 ES genes are listed in Table <xref rid="tbl1" ref-type="table">1</xref>. For individual lost protein feature categories, we did over-representation analysis using Gene Set Enrichment Analysis (GSEA) to determine if the number of genes in each category is &gt;30 and &lt;700. This is a modified range from GSEA’s default range (25–500). There are 18 feature categories in total (Figure <xref ref-type="fig" rid="F2">2</xref>). We then found that the genes that lost the ‘molecule processing’ subsection were enriched in biological processes related to the ‘regulation of immune system process’, ‘cellular respiration’, and ‘proteolysis’. The genes that lost the ‘regions’ subsection were enriched in ‘protein localization’, ‘regulation of transcription from RNA polymerase II promoter’, ‘microtubule-based process’ and ‘positive regulation of gene expression’. Specifically, the genes that lost ‘compositional bias’ features were enriched in ‘positive regulation of gene expression’ as described as important in gene expression regulations in many reports (<xref rid="B37" ref-type="bibr">37–39</xref>). The genes that lost the ‘amino acid modifications’ subsection were enriched in the ‘biological adhesion’ process, consistent with previous studies about the needs of amino acid modifications for improving cell adhesions (<xref rid="B40" ref-type="bibr">40</xref>,<xref rid="B41" ref-type="bibr">41</xref>). Interestingly, the genes that lost the ‘sites’ subsection were enriched in the ‘small molecular metabolic processes’. Of 554 genes that lost this subsection, 118 genes are drug targets according to the International Union of Basic and Clinical Pharmacology (IUPHAR) (<xref rid="B42" ref-type="bibr">42</xref>). We identified 66 out of 118 genes that can be targeted by 136 approved drugs from DrugBank and 120 drugs are small molecule drug types. In addition, we found that 142 genes lost specific amino acid sites, such as ‘the site required for ligand-induced CBL-mediated ubiquitination’ in <italic>MET</italic> exon 14 skipping event. Overall, there were 21, 30, 16, 23, 23 and 4 sites of breakpoint, cleavage, important, inhibition, interaction, and required sites according to UniProt feature description, respectively. For 20 genes overlapped with important group genes out of 121 cancer-specific ES genes, we focused on studying the lost protein functional features (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S15</xref>). These 20 genes lost extracellular membrane domain, transmembrane domain, protein kinase domain, nuclear receptor, tyrosine–protein phosphatase, so on. Changes in the functional features due to these ES events can serve as a good resource for further validation of ES-caused tumorigenesis.</p>
      <table-wrap id="tbl1" orientation="portrait" position="float">
        <label>Table 1.</label>
        <caption>
          <p>Number of in-frame ES event genes per lost protein functional features</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Subsection</th>
              <th rowspan="1" colspan="1">Content</th>
              <th rowspan="1" colspan="1"># in-frame exon skipped genes</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Molecule processing</td>
              <td rowspan="1" colspan="1">Initiator methionine</td>
              <td rowspan="1" colspan="1">13</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Signal peptide</td>
              <td rowspan="1" colspan="1">93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Transit peptide</td>
              <td rowspan="1" colspan="1">31</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Propeptide</td>
              <td rowspan="1" colspan="1">45</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Chain</td>
              <td rowspan="1" colspan="1">7044</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Peptide</td>
              <td rowspan="1" colspan="1">8</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Regions</td>
              <td rowspan="1" colspan="1">Topological domain</td>
              <td rowspan="1" colspan="1">1243</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Transmembrane</td>
              <td rowspan="1" colspan="1">847</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Intramembrane</td>
              <td rowspan="1" colspan="1">21</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Domain</td>
              <td rowspan="1" colspan="1">2427</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Repeat</td>
              <td rowspan="1" colspan="1">596</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Calcium binding</td>
              <td rowspan="1" colspan="1">25</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Zinc finger</td>
              <td rowspan="1" colspan="1">193</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">DNA binding</td>
              <td rowspan="1" colspan="1">21</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Nucleotide binding</td>
              <td rowspan="1" colspan="1">269</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Region</td>
              <td rowspan="1" colspan="1">1055</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Coiled coil</td>
              <td rowspan="1" colspan="1">458</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Motif</td>
              <td rowspan="1" colspan="1">192</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Compositional bias</td>
              <td rowspan="1" colspan="1">497</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Sites</td>
              <td rowspan="1" colspan="1">Active site</td>
              <td rowspan="1" colspan="1">240</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Metal binding</td>
              <td rowspan="1" colspan="1">237</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Binding site</td>
              <td rowspan="1" colspan="1">378</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Site</td>
              <td rowspan="1" colspan="1">142</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Amino acid modifications</td>
              <td rowspan="1" colspan="1">Modified residue</td>
              <td rowspan="1" colspan="1">1374</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Lipidation</td>
              <td rowspan="1" colspan="1">18</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Glycosylation</td>
              <td rowspan="1" colspan="1">624</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Disulfide bond</td>
              <td rowspan="1" colspan="1">647</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Cross-link</td>
              <td rowspan="1" colspan="1">234</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Natural variations</td>
              <td rowspan="1" colspan="1">Alternative sequence</td>
              <td rowspan="1" colspan="1">3123</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Natural variant</td>
              <td rowspan="1" colspan="1">2080</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Experimental info</td>
              <td rowspan="1" colspan="1">Mutagenesis</td>
              <td rowspan="1" colspan="1">665</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Sequence conflict</td>
              <td rowspan="1" colspan="1">1482</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Secondary structure</td>
              <td rowspan="1" colspan="1">Helix</td>
              <td rowspan="1" colspan="1">1750</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Turn</td>
              <td rowspan="1" colspan="1">952</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Beta strand</td>
              <td rowspan="1" colspan="1">1623</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig id="F2" orientation="portrait" position="float">
        <label>Figure 2.</label>
        <caption>
          <p>The overrepresentation enrichment analysis of ES genes per lost protein feature categories. For individual protein functional feature categories, which were lost in ES genes due to exons kipping, we have investigated the enriched genes in the biological processes. The abbreviations of categories are following with alphabetical order; Active site (AS), Binding site (BS), Coiled coil (CC), Compositional bias (CB), Cross-link (CL), Disulfide bond (DB), Glycosylation (G), Metal binding (MB), Motif (MB), Mutagenesis (MUT), Nucleotide binding (NB), Propeptide (PP), Repeat (R), Signal peptide (SP), Site (SP), Transit peptide (TP) and Zinc finger (ZF). In the left top panel, SP, TP, and PP belong to the UniProt's protein feature subsection of ‘Molecule processing’, and R, ZF, NB, CC, M and CB belong to the ‘Regions’ subsection. In the right top panel, AS, MS, BS and S belong to the ‘Sites’ subsection. G, DB and CL belong to the subsection of ‘Amino acid modifications’. Lastly, Mutagenesis (M) belongs to the ‘Experimental info’ subsection.</p>
        </caption>
        <graphic xlink:href="gkz917fig2"/>
      </fig>
    </sec>
    <sec id="SEC4-4">
      <title>Non-synonymous mutation-associated exon skipping events</title>
      <p>As we have seen from the mutation-induced exon skipping examples (such as <italic>MET</italic> exon 14 and <italic>DMD</italic> exon skipping), screening mutations associated with exon skipping events are a good approach to identify novel therapeutic targets. By overlapping genomic coordinates of somatic mutations including splice-site, nonsense, and frame-shift mutations (see Materials and Methods for the reason why we focused on these mutation types), and ES loci, we identified 11 204 genes with 75 130 non-synonymous mutations in 35 714 ES events. For 7139 cancer samples with non-synonymous mutations and available bam files, we plotted their coverage depth along the three exons of each ES event. Among them, we selected 136 ES events in 123 genes as shown in Table <xref rid="tbl2" ref-type="table">2</xref>. These events have decreased coverage depth at the skipped exon and differential in PSI values between mutated and non-mutated samples (see Methods). Taking <italic>MET</italic> as an example, as shown in Figure <xref ref-type="fig" rid="F1">1E</xref>, in a LUAD sample with ‘p.D1010_splice’ mutation, the read coverage depth of the skipped exon is decreased by more than 1000.0 reads. Second, there is a difference in the distribution of PSI values between the samples with mutations and wild-type. Furthermore, the sashimi plot showed almost of the split reads were connected between the two flanking exons. Of the 123 mutation candidate genes associated with exon skipping, 8 ES events (7 genes) have more than 2 mutated samples in each cancer type. These ES events are <italic>IRF3</italic>, <italic>MET</italic>, <italic>PIK3R1</italic>, <italic>PTEN</italic>, <italic>SCRIB</italic>, <italic>TP53</italic> and <italic>YLPM1</italic>. In addition, <italic>PLEC</italic> and <italic>RB1</italic> have more than two mutated samples in pan-cancer.</p>
      <table-wrap id="tbl2" orientation="portrait" position="float">
        <label>Table 2.</label>
        <caption>
          <p>Exon skipping events associated with mutations</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Gene</th>
              <th rowspan="1" colspan="1">Cancer type</th>
              <th rowspan="1" colspan="1">ESID</th>
              <th rowspan="1" colspan="1">Gene</th>
              <th rowspan="1" colspan="1">Cancer type</th>
              <th rowspan="1" colspan="1">ESID</th>
              <th rowspan="1" colspan="1">Gene</th>
              <th rowspan="1" colspan="1">Cancer type</th>
              <th rowspan="1" colspan="1">ESID</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">AASS</td>
              <td rowspan="1" colspan="1">BRCA</td>
              <td rowspan="1" colspan="1">exon_skip_479254</td>
              <td rowspan="1" colspan="1">HNRNPC</td>
              <td rowspan="1" colspan="1">READ</td>
              <td rowspan="1" colspan="1">exon_skip_111139</td>
              <td rowspan="1" colspan="1">RASA1</td>
              <td rowspan="1" colspan="1">HNSC</td>
              <td rowspan="1" colspan="1">exon_skip_436351</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ACADVL</td>
              <td rowspan="1" colspan="1">HNSC</td>
              <td rowspan="1" colspan="1">exon_skip_148534</td>
              <td rowspan="1" colspan="1">IRF3</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_320801</td>
              <td rowspan="1" colspan="1">RB1</td>
              <td rowspan="1" colspan="1">LGG</td>
              <td rowspan="1" colspan="1">exon_skip_100319</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ACE2</td>
              <td rowspan="1" colspan="1">LIHC</td>
              <td rowspan="1" colspan="1">exon_skip_514046</td>
              <td rowspan="1" colspan="1">IRF3</td>
              <td rowspan="1" colspan="1">LIHC</td>
              <td rowspan="1" colspan="1">exon_skip_320801</td>
              <td rowspan="1" colspan="1">RB1</td>
              <td rowspan="1" colspan="1">LUSC</td>
              <td rowspan="1" colspan="1">exon_skip_100319</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ACSL1</td>
              <td rowspan="1" colspan="1">BRCA</td>
              <td rowspan="1" colspan="1">exon_skip_433327</td>
              <td rowspan="1" colspan="1">KCTD10</td>
              <td rowspan="1" colspan="1">STAD</td>
              <td rowspan="1" colspan="1">exon_skip_96034</td>
              <td rowspan="1" colspan="1">RB1</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_100319</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ACTR5</td>
              <td rowspan="1" colspan="1">HNSC</td>
              <td rowspan="1" colspan="1">exon_skip_351842</td>
              <td rowspan="1" colspan="1">KDM4C</td>
              <td rowspan="1" colspan="1">LIHC</td>
              <td rowspan="1" colspan="1">exon_skip_495073</td>
              <td rowspan="1" colspan="1">RB1</td>
              <td rowspan="1" colspan="1">SARC</td>
              <td rowspan="1" colspan="1">exon_skip_100320</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">AK9</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_461739</td>
              <td rowspan="1" colspan="1">LAMTOR4</td>
              <td rowspan="1" colspan="1">CESC</td>
              <td rowspan="1" colspan="1">exon_skip_468895</td>
              <td rowspan="1" colspan="1">RB1</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_100321</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">AP1G2</td>
              <td rowspan="1" colspan="1">KIRP</td>
              <td rowspan="1" colspan="1">exon_skip_111822</td>
              <td rowspan="1" colspan="1">LPCAT1</td>
              <td rowspan="1" colspan="1">COAD</td>
              <td rowspan="1" colspan="1">exon_skip_440961</td>
              <td rowspan="1" colspan="1">RBBP7</td>
              <td rowspan="1" colspan="1">BRCA</td>
              <td rowspan="1" colspan="1">exon_skip_514095</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">AP1G2</td>
              <td rowspan="1" colspan="1">UCS</td>
              <td rowspan="1" colspan="1">exon_skip_111839</td>
              <td rowspan="1" colspan="1">LRRC37B</td>
              <td rowspan="1" colspan="1">TGCT</td>
              <td rowspan="1" colspan="1">exon_skip_150743</td>
              <td rowspan="1" colspan="1">RBL2</td>
              <td rowspan="1" colspan="1">LIHC</td>
              <td rowspan="1" colspan="1">exon_skip_136487</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ARAP1</td>
              <td rowspan="1" colspan="1">HNSC</td>
              <td rowspan="1" colspan="1">exon_skip_75409</td>
              <td rowspan="1" colspan="1">LRRC49</td>
              <td rowspan="1" colspan="1">LUSC</td>
              <td rowspan="1" colspan="1">exon_skip_123285</td>
              <td rowspan="1" colspan="1">RBM10</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_509946</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ARAP2</td>
              <td rowspan="1" colspan="1">STAD</td>
              <td rowspan="1" colspan="1">exon_skip_428975</td>
              <td rowspan="1" colspan="1">LZTFL1</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_382808</td>
              <td rowspan="1" colspan="1">RBM11</td>
              <td rowspan="1" colspan="1">CESC</td>
              <td rowspan="1" colspan="1">exon_skip_358911</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ARHGAP4</td>
              <td rowspan="1" colspan="1">CESC</td>
              <td rowspan="1" colspan="1">exon_skip_517379</td>
              <td rowspan="1" colspan="1">MAOB</td>
              <td rowspan="1" colspan="1">LIHC</td>
              <td rowspan="1" colspan="1">exon_skip_514541</td>
              <td rowspan="1" colspan="1">RBM23</td>
              <td rowspan="1" colspan="1">KIRP</td>
              <td rowspan="1" colspan="1">exon_skip_111436</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ARSA</td>
              <td rowspan="1" colspan="1">ESCA</td>
              <td rowspan="1" colspan="1">exon_skip_370946</td>
              <td rowspan="1" colspan="1">MAP4K4</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_328236</td>
              <td rowspan="1" colspan="1">RBM27</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_438439</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ATF7IP</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_80383</td>
              <td rowspan="1" colspan="1">MCTP2</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_125176</td>
              <td rowspan="1" colspan="1">RWDD2B</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_361480</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ATXN7L1</td>
              <td rowspan="1" colspan="1">BRCA</td>
              <td rowspan="1" colspan="1">exon_skip_478799</td>
              <td rowspan="1" colspan="1">MET</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_470683</td>
              <td rowspan="1" colspan="1">SAAL1</td>
              <td rowspan="1" colspan="1">LIHC</td>
              <td rowspan="1" colspan="1">exon_skip_69749</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">AXIN1</td>
              <td rowspan="1" colspan="1">LIHC</td>
              <td rowspan="1" colspan="1">exon_skip_140168</td>
              <td rowspan="1" colspan="1">MFN1</td>
              <td rowspan="1" colspan="1">BRCA</td>
              <td rowspan="1" colspan="1">exon_skip_379593</td>
              <td rowspan="1" colspan="1">SAFB</td>
              <td rowspan="1" colspan="1">LUSC</td>
              <td rowspan="1" colspan="1">exon_skip_301206</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">BAP1</td>
              <td rowspan="1" colspan="1">UVM</td>
              <td rowspan="1" colspan="1">exon_skip_384821</td>
              <td rowspan="1" colspan="1">MFSD11</td>
              <td rowspan="1" colspan="1">BRCA</td>
              <td rowspan="1" colspan="1">exon_skip_156579</td>
              <td rowspan="1" colspan="1">SCRIB</td>
              <td rowspan="1" colspan="1">STAD</td>
              <td rowspan="1" colspan="1">exon_skip_493826</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">BCHE</td>
              <td rowspan="1" colspan="1">LIHC</td>
              <td rowspan="1" colspan="1">exon_skip_389735</td>
              <td rowspan="1" colspan="1">MIB2</td>
              <td rowspan="1" colspan="1">LIHC</td>
              <td rowspan="1" colspan="1">exon_skip_292</td>
              <td rowspan="1" colspan="1">SEMA6C</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_30610</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">BRCC3</td>
              <td rowspan="1" colspan="1">READ</td>
              <td rowspan="1" colspan="1">exon_skip_513411</td>
              <td rowspan="1" colspan="1">MPP1</td>
              <td rowspan="1" colspan="1">LIHC</td>
              <td rowspan="1" colspan="1">exon_skip_517757</td>
              <td rowspan="1" colspan="1">SIK3</td>
              <td rowspan="1" colspan="1">BRCA</td>
              <td rowspan="1" colspan="1">exon_skip_77623</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">BSDC1</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_24351</td>
              <td rowspan="1" colspan="1">MPP1</td>
              <td rowspan="1" colspan="1">LIHC</td>
              <td rowspan="1" colspan="1">exon_skip_517758</td>
              <td rowspan="1" colspan="1">SLC44A1</td>
              <td rowspan="1" colspan="1">LUSC</td>
              <td rowspan="1" colspan="1">exon_skip_497929</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">BSDC1</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_24356</td>
              <td rowspan="1" colspan="1">MSH2</td>
              <td rowspan="1" colspan="1">STAD</td>
              <td rowspan="1" colspan="1">exon_skip_325448</td>
              <td rowspan="1" colspan="1">SLC6A9</td>
              <td rowspan="1" colspan="1">BRCA</td>
              <td rowspan="1" colspan="1">exon_skip_25867</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">C16orf70</td>
              <td rowspan="1" colspan="1">OV</td>
              <td rowspan="1" colspan="1">exon_skip_137511</td>
              <td rowspan="1" colspan="1">MSI2</td>
              <td rowspan="1" colspan="1">SARC</td>
              <td rowspan="1" colspan="1">exon_skip_154718</td>
              <td rowspan="1" colspan="1">SLCO2A1</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_388682</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">C20orf96</td>
              <td rowspan="1" colspan="1">LGG</td>
              <td rowspan="1" colspan="1">exon_skip_354191</td>
              <td rowspan="1" colspan="1">MYO9B</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_303297</td>
              <td rowspan="1" colspan="1">SMARCA1</td>
              <td rowspan="1" colspan="1">KIRP</td>
              <td rowspan="1" colspan="1">exon_skip_516648</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CCDC125</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_442509</td>
              <td rowspan="1" colspan="1">NF1</td>
              <td rowspan="1" colspan="1">PCPG</td>
              <td rowspan="1" colspan="1">exon_skip_150648</td>
              <td rowspan="1" colspan="1">SMARCA2</td>
              <td rowspan="1" colspan="1">KIRC</td>
              <td rowspan="1" colspan="1">exon_skip_494778</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CCDC90B</td>
              <td rowspan="1" colspan="1">HNSC</td>
              <td rowspan="1" colspan="1">exon_skip_76335</td>
              <td rowspan="1" colspan="1">NF2</td>
              <td rowspan="1" colspan="1">CHOL</td>
              <td rowspan="1" colspan="1">exon_skip_364330</td>
              <td rowspan="1" colspan="1">SMARCC1</td>
              <td rowspan="1" colspan="1">HNSC</td>
              <td rowspan="1" colspan="1">exon_skip_383264</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CD44</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_57862</td>
              <td rowspan="1" colspan="1">NSFL1C</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_354315</td>
              <td rowspan="1" colspan="1">SNRNP200</td>
              <td rowspan="1" colspan="1">KIRP</td>
              <td rowspan="1" colspan="1">exon_skip_341775</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CDH1</td>
              <td rowspan="1" colspan="1">BRCA</td>
              <td rowspan="1" colspan="1">exon_skip_138094</td>
              <td rowspan="1" colspan="1">OCIAD1</td>
              <td rowspan="1" colspan="1">LGG</td>
              <td rowspan="1" colspan="1">exon_skip_423495</td>
              <td rowspan="1" colspan="1">SPCS1</td>
              <td rowspan="1" colspan="1">HNSC</td>
              <td rowspan="1" colspan="1">exon_skip_375123</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CHD3</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_148936</td>
              <td rowspan="1" colspan="1">OCRL</td>
              <td rowspan="1" colspan="1">LUSC</td>
              <td rowspan="1" colspan="1">exon_skip_512323</td>
              <td rowspan="1" colspan="1">STAG2</td>
              <td rowspan="1" colspan="1">GBM</td>
              <td rowspan="1" colspan="1">exon_skip_512303</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CHEK2</td>
              <td rowspan="1" colspan="1">LUSC</td>
              <td rowspan="1" colspan="1">exon_skip_368202</td>
              <td rowspan="1" colspan="1">ODF2</td>
              <td rowspan="1" colspan="1">PAAD</td>
              <td rowspan="1" colspan="1">exon_skip_499697</td>
              <td rowspan="1" colspan="1">SUPT3H</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_459890</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CNOT6</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_440379</td>
              <td rowspan="1" colspan="1">PACRGL</td>
              <td rowspan="1" colspan="1">LUSC</td>
              <td rowspan="1" colspan="1">exon_skip_422774</td>
              <td rowspan="1" colspan="1">TBL1X</td>
              <td rowspan="1" colspan="1">UCEC</td>
              <td rowspan="1" colspan="1">exon_skip_509098</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">COL13A1</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_42139</td>
              <td rowspan="1" colspan="1">PEA15</td>
              <td rowspan="1" colspan="1">LGG</td>
              <td rowspan="1" colspan="1">exon_skip_12856</td>
              <td rowspan="1" colspan="1">TBX3</td>
              <td rowspan="1" colspan="1">STAD</td>
              <td rowspan="1" colspan="1">exon_skip_96977</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">COL7A1</td>
              <td rowspan="1" colspan="1">LUSC</td>
              <td rowspan="1" colspan="1">exon_skip_383673</td>
              <td rowspan="1" colspan="1">PELI2</td>
              <td rowspan="1" colspan="1">LUSC</td>
              <td rowspan="1" colspan="1">exon_skip_106790</td>
              <td rowspan="1" colspan="1">TCTN2</td>
              <td rowspan="1" colspan="1">THCA</td>
              <td rowspan="1" colspan="1">exon_skip_88383</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">COPS3</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_287002</td>
              <td rowspan="1" colspan="1">PGLYRP2</td>
              <td rowspan="1" colspan="1">LIHC</td>
              <td rowspan="1" colspan="1">exon_skip_316122</td>
              <td rowspan="1" colspan="1">TEP1</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_110964</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CREBBP</td>
              <td rowspan="1" colspan="1">CESC</td>
              <td rowspan="1" colspan="1">exon_skip_141389</td>
              <td rowspan="1" colspan="1">PHKA2</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_514168</td>
              <td rowspan="1" colspan="1">TERF1</td>
              <td rowspan="1" colspan="1">OV</td>
              <td rowspan="1" colspan="1">exon_skip_484059</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CTCF</td>
              <td rowspan="1" colspan="1">BRCA</td>
              <td rowspan="1" colspan="1">exon_skip_137805</td>
              <td rowspan="1" colspan="1">PHKA2</td>
              <td rowspan="1" colspan="1">BRCA</td>
              <td rowspan="1" colspan="1">exon_skip_514195</td>
              <td rowspan="1" colspan="1">TNFRSF10A</td>
              <td rowspan="1" colspan="1">PAAD</td>
              <td rowspan="1" colspan="1">exon_skip_488782</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">DIAPH3</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_103986</td>
              <td rowspan="1" colspan="1">PIK3R1</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_435166</td>
              <td rowspan="1" colspan="1">TP53</td>
              <td rowspan="1" colspan="1">OV</td>
              <td rowspan="1" colspan="1">exon_skip_286364</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">DLG3</td>
              <td rowspan="1" colspan="1">STAD</td>
              <td rowspan="1" colspan="1">exon_skip_511069</td>
              <td rowspan="1" colspan="1">PIK3R1</td>
              <td rowspan="1" colspan="1">COAD</td>
              <td rowspan="1" colspan="1">exon_skip_435167</td>
              <td rowspan="1" colspan="1">TP53</td>
              <td rowspan="1" colspan="1">OV</td>
              <td rowspan="1" colspan="1">exon_skip_286376</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">DSG2</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_296226</td>
              <td rowspan="1" colspan="1">PLEC</td>
              <td rowspan="1" colspan="1">LUSC</td>
              <td rowspan="1" colspan="1">exon_skip_494000</td>
              <td rowspan="1" colspan="1">TP53</td>
              <td rowspan="1" colspan="1">UCS</td>
              <td rowspan="1" colspan="1">exon_skip_286379</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">EEA1</td>
              <td rowspan="1" colspan="1">STAD</td>
              <td rowspan="1" colspan="1">exon_skip_95294</td>
              <td rowspan="1" colspan="1">PLEC</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_494000</td>
              <td rowspan="1" colspan="1">TP53</td>
              <td rowspan="1" colspan="1">BRCA</td>
              <td rowspan="1" colspan="1">exon_skip_286384</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">EPB41L4A</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_443476</td>
              <td rowspan="1" colspan="1">PLOD3</td>
              <td rowspan="1" colspan="1">LUSC</td>
              <td rowspan="1" colspan="1">exon_skip_478451</td>
              <td rowspan="1" colspan="1">TP53</td>
              <td rowspan="1" colspan="1">KICH</td>
              <td rowspan="1" colspan="1">exon_skip_286388</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">FARP2</td>
              <td rowspan="1" colspan="1">ESCA</td>
              <td rowspan="1" colspan="1">exon_skip_336006</td>
              <td rowspan="1" colspan="1">PPP6C</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_506902</td>
              <td rowspan="1" colspan="1">TRAPPC2L</td>
              <td rowspan="1" colspan="1">BRCA</td>
              <td rowspan="1" colspan="1">exon_skip_139393</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">FAS</td>
              <td rowspan="1" colspan="1">DLBC</td>
              <td rowspan="1" colspan="1">exon_skip_43777</td>
              <td rowspan="1" colspan="1">PROM1</td>
              <td rowspan="1" colspan="1">BRCA</td>
              <td rowspan="1" colspan="1">exon_skip_428630</td>
              <td rowspan="1" colspan="1">TULP4</td>
              <td rowspan="1" colspan="1">BRCA</td>
              <td rowspan="1" colspan="1">exon_skip_455061</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">FN1</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_346530</td>
              <td rowspan="1" colspan="1">PTCH1</td>
              <td rowspan="1" colspan="1">ESCA</td>
              <td rowspan="1" colspan="1">exon_skip_505102</td>
              <td rowspan="1" colspan="1">UBE2D3</td>
              <td rowspan="1" colspan="1">LIHC</td>
              <td rowspan="1" colspan="1">exon_skip_431479</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GCSAM</td>
              <td rowspan="1" colspan="1">DLBC</td>
              <td rowspan="1" colspan="1">exon_skip_386471</td>
              <td rowspan="1" colspan="1">PTEN</td>
              <td rowspan="1" colspan="1">COAD</td>
              <td rowspan="1" colspan="1">exon_skip_43702</td>
              <td rowspan="1" colspan="1">UBE2E1</td>
              <td rowspan="1" colspan="1">CESC</td>
              <td rowspan="1" colspan="1">exon_skip_372157</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GLRX3</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_46116</td>
              <td rowspan="1" colspan="1">PTEN</td>
              <td rowspan="1" colspan="1">CESC</td>
              <td rowspan="1" colspan="1">exon_skip_43707</td>
              <td rowspan="1" colspan="1">USP40</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_347441</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GNB5</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_127162</td>
              <td rowspan="1" colspan="1">PTEN</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_43707</td>
              <td rowspan="1" colspan="1">YIF1A</td>
              <td rowspan="1" colspan="1">STAD</td>
              <td rowspan="1" colspan="1">exon_skip_74538</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GPR143</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_513862</td>
              <td rowspan="1" colspan="1">PTEN</td>
              <td rowspan="1" colspan="1">BRCA</td>
              <td rowspan="1" colspan="1">exon_skip_43714</td>
              <td rowspan="1" colspan="1">YLPM1</td>
              <td rowspan="1" colspan="1">SKCM</td>
              <td rowspan="1" colspan="1">exon_skip_108215</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">HAUS6</td>
              <td rowspan="1" colspan="1">STAD</td>
              <td rowspan="1" colspan="1">exon_skip_502793</td>
              <td rowspan="1" colspan="1">RABL3</td>
              <td rowspan="1" colspan="1">LUSC</td>
              <td rowspan="1" colspan="1">exon_skip_386919</td>
              <td rowspan="1" colspan="1">ZNF512B</td>
              <td rowspan="1" colspan="1">LUAD</td>
              <td rowspan="1" colspan="1">exon_skip_358876</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>After manually curating the evidence of ES-associated mutation in these 9 genes, we identified a novel mutation-associated exon skipping event of <italic>RB1</italic> (RB transcriptional corepressor 1), as shown in Figure <xref ref-type="fig" rid="F3">3</xref>. <italic>RB1</italic> is a negative regulator of the cell cycle. The RB1 protein also stabilizes constitutive heterochromatin to maintain overall chromatin structure. The active hypo-phosphorylated RB1 protein binds to transcription factor E2F1 (<xref rid="B32" ref-type="bibr">32</xref>). There are 9 samples with five splice-site and nonsense mutations in ‘exon_skip_100319’ ES event of <italic>RB1</italic> (Figure <xref ref-type="fig" rid="F3">3A</xref>). Three of them are located in the splice acceptor or donor sites of the skipped exon. The nonsense mutation is p.R455* of <italic>RB1</italic>. Samples with these mutations showed different PSI values than the non-mutated ones, and the coverage depth decreased consistently (Figure <xref ref-type="fig" rid="F3">3B</xref>). Since this ES event was predicted to create an in-frame ORF transcript (Figure <xref ref-type="fig" rid="F3">3C</xref>), annotation of lost protein features due to this in-frame ORF ES event can be achieved with ExonSkipDB (Figure <xref ref-type="fig" rid="F3">3D</xref>). This ES event seems to cause a loss of a portion of the ‘pocket’ (retinoblastoma associated protein A domain) between 444 to 463 amino acid sequence. In addition, <italic>RB1</italic> exon skipping event caused by mutations in the splice site may result in the loss of normal RB1 function through binding and inhibiting E2F-DP dimer formation (E2 promoter-binding-protein-dimerization partner), thereby restricting cell replication.</p>
      <fig id="F3" orientation="portrait" position="float">
        <label>Figure 3.</label>
        <caption>
          <p>Splice-site mutation associated exon skipping event in RB1. Among 10 recurrent ES events, RB1 showed consistent expression change and differential PSI values with non-mutated samples in multiple cancer types. (<bold>A</bold>) Mutations associated with exon skipping event (ESID: exon_skip_100319) in RB1 and mutation location in the gene structure. (<bold>B</bold>) RNA-seq evidence for the mutation associated exon skipping event. Consistent evidence through the depth of coverage, differential PSI values between mutated and non-mutated samples, and sashimi plots. (<bold>C</bold>) The analyzed ORF information of individual exon skipping events based on the canonical transcript sequence. (<bold>D</bold>) The protein functional features based on the canonical protein sequence.</p>
        </caption>
        <graphic xlink:href="gkz917fig3"/>
      </fig>
      <p>Another candidate is interferon regulatory factor 3 (<italic>IRF3</italic>). As shown in <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S3</xref>, ‘exon_skip_320801’ ES event location covers partial of 5′-UTR and CDS. Two LIHC (Liver Hepatocellular Carcinoma) and three SKCM (Skin Cutaneous Melanoma) samples had ‘Frame_shift_Indel' or ‘Nonsense' mutations in this skipped exons. These samples showed decreased read coverage depth and differential PSI values between mutated and non-mutated samples. Overall translation rates were also affected by characteristics of the 5′-UTR, including length and start-site consensus sequences, the presence of secondary structure, upstream AUGs, upstream open reading frames (uORFs) and internal ribosome entry sites (IRES) (<xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B44" ref-type="bibr">44</xref>). In addition, 5′-UTRs can contain sequences that function as binding sites for regulatory proteins (<xref rid="B45" ref-type="bibr">45</xref>). In this context, we have searched binding sites by the known transcription factors of <italic>IRF3</italic> (such as AP1, ATF2, NF-kappaB, NF-kappaB1, p300, p53 and STAT1) in this ES location (chr19:50164706–50165585) from GeneCards (<xref rid="B46" ref-type="bibr">46</xref>) using ConTra v3, a tool for identifying transcription factor binding sites (<xref rid="B47" ref-type="bibr">47</xref>). As shown in <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S4</xref>, we predicted three and one binding sites of the p300 and ATF2 proteins in the partial 5′-UTR of ‘exon_skip_32080’ ES event. Furthermore, analysis of the lost protein functional features showing in <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S3C</xref> indicates the skipped exon may lead to the loss of the ‘HERC5 binding site’ in the CSD portion. In summary, loss of functional and regulatory domains caused by this ES event may result in IRF3 dysfunction. These findings require further experimental validation. ExonSkipDB can also provide ES event located mutation information for public cell lines by integrating data from Cancer Cell Line Encyclopedia (CCLE) (<xref rid="B48" ref-type="bibr">48</xref>), In total, we found that 1570 cell-lines have overlaps with 243 628 ES-region mutations of TCGA samples across 12 368 genes. This information can be downloaded from the ExonSkipDB web site.</p>
    </sec>
    <sec id="SEC4-5">
      <title>Exon skipping associated sQTLs and sQTMs</title>
      <p>SNPs can alter splicing or alternative splicing by altering the sequence-specific binding affinity of the splicing factors to the pre-mRNAs, resulting splicing quantitative trait locus (sQTL) (<xref rid="B49" ref-type="bibr">49</xref>). To explore the association of exon skipping with sQTLs and sQTMs, we downloaded 901 167 sQTL candidate SNPs in 9909 genes of 33 cancer types from TCGA (<xref rid="B12" ref-type="bibr">12</xref>). By integrating these sQTLs with skipped exon loci, we identified 4124 SNPs located in 4298 skipped exons of 2254 genes. Of these, 51 SNPs in 50 genes were completely overlapped with SNVs in 40 TCGA samples. These genes are mainly involved in ‘regulation of cell proliferation’, ‘positive regulation of protein metabolic process’, and ‘phosphorylation’ (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S16</xref>).</p>
      <p>DNA methylation was originally thought only affecting transcription. Emerging evidence shows that methylation also regulates alternative splicing of RNA (<xref rid="B17" ref-type="bibr">17</xref>). Three proteins are known to transmit DNA methylation-encoded information to splicing machinery through different mechanisms, including CTCF, methyl-CpG binding protein 2 (MeCP2), and HP1. CTCF can bind to DNA and reduce the elongation rate of Pol II, which facilitates exon inclusion. In this process, CTCF binding can be inhibited by DNA methylation. Therefore, DNA methylation can result in exon exclusion (<xref rid="B50" ref-type="bibr">50</xref>). Second, the binding of MeCP2 to the methylated DNA can reduce the elongation rate of Pol II, enhancing exon inclusion (<xref rid="B51" ref-type="bibr">51</xref>). Another mechanism involves in the formation of protein bridges, through which DNA methylation leads to histone modification of H3K9me3. At the chromatin level, HP1 proteins can accumulate on the regulated alternative exons and then HP1-bound splicing factors can exert their regulatory role on these alternative exons (<xref rid="B52" ref-type="bibr">52</xref>). More underlying mechanisms are remained to be identified. Since TCGA has DNA methylation and RNA-Seq data for the matched samples, we explored the regulatory mechanisms of DNA methylation on alternative splicing. PSI values measure how efficiently the sequences of interest are spliced into transcripts (<xref rid="B53" ref-type="bibr">53</xref>). We downloaded PSI values from the studies conducted by Kahles <italic>et al.</italic> (<xref rid="B12" ref-type="bibr">12</xref>) and calculated the average beta values of CpG methylations in the upstream region covering the two upstream exons in three ES-involved exons. We then used MatrixEQTL to identify significantly associated methylation-ES pairs in pan-cancer. The same approach was also used to identify cancer type-specific ES-specific sQTMs and prognostic candidate pairs. We set the threshold of significant sQTM pairs with a <italic>p</italic>-value less than 1.0 × e−5.</p>
      <p>Using this approach, we identified 513 significant sQTM pairs of 434 genes. Among these sQTMs, 292 and 218 sQTM pairs had negative and positive correlations with exon skipping events, respectively. We analyzed the overrepresented biological processes (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S17</xref>) for these sQTM genes. The positively correlated genes were enriched in the process of ‘positive regulation of response to stimulus or cell communications’. The negatively correlated genes were actively involved in ‘macromolecular complex assembly’, ‘regulation of transcription from RNA polymerase II promoter’, ‘positive regulation of gene expression’, and ‘cellular response to stress’. This different roles in the cells might depend on the methylation locations across genes. We also examined the overlap between somatic mutation loci and 513 sQTMs’ exons. There were 192 TCGA samples with 140 mutations in the skipped exons of 125 ES genes. Interestingly, these somatically mutated sQTM genes were involved in the same biological processes as the 40 genes with mutated sQTLs (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S18</xref>). In addition, 77 exon skipping events (out of 513 sQTM exons) of the 67 genes were common in more than 2 cancer types. On the other hand, 146 exon skipping events in 137 genes were cancer type-specific sQTMs pairs with mutual exclusivity. For the PSI and beta values of these sQTMs, we generated t-distributed stochastic neighbor embedding (t-SNE) plots (see the statistics page of the ExonSkipDB web site). These images show the dispersion of each value in pan-cancer with a cancer type-specific distribution. For all sQTM pairs, we performed survival analysis and identified 50 prognostic sQTMs. One of the top-ranked prognostic sQTM genes was deoxythymidylate kinase (<italic>DTYMK</italic>) (<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S5</xref>). This gene was reported as a potential marker for brain tumors in cerebrospinal fluid (<xref rid="B54" ref-type="bibr">54</xref>).</p>
    </sec>
    <sec id="SEC4-6">
      <title>ES gene-related FDA approved-drugs and human diseases</title>
      <p>The pharmacological information related to the ES genes were obtained from DrugBank (<xref rid="B18" ref-type="bibr">18</xref>). Our analysis indicates that 1801 proteins encoded by ES genes are targeted by 1676 drugs. Among these, 1534 (91.50%) are FDA-approved drugs targeting 1715 proteins. 750, 142, 104, 93, 74 and 67 drugs targeted ‘cellular receptors’, ‘channels’, ‘transporters’, ‘synthases’, ‘kinases’, and ‘growth factors’, respectively. Related disease category shows the related disease information for each gene from a database of gene-disease associations (DisGeNet) (<xref rid="B19" ref-type="bibr">19</xref>). We found that the identified 7324 exon skipping events-related genes were associated with 5039 different types of diseases based on the published data searches. Of these, 955 genes were associated with 711 different syndromes.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC5">
    <title>DISCUSSION AND FUTURE DIRECTION</title>
    <p>ExonSkipDB is the first database to systematically annotate the function of exon skipping events across human pan-cancer and multiple human tissues. To serve the broad biomedical research communities, we will continually update and curate exon skipping events by routinely checking newly published alternative splicing data sets for human diseases, including neurodegenerative diseases such as Alzheimer's disease. To make better use of ExonSkipDB, we will add the analysis results for the exon skipping events from over 1000 cell-lines in CCLE, as well as data sets for multiple mouse tissues. We will continue to expand our research and improve our approach to find clinically significant exon skip events and downstream target genes. The user-friendly website provides researchers with multiple annotations and facilitates a comprehensive functional study of exon skipping. Therefore, ExonSkipDB will be useful resource for many researchers in the fields of pathology, cancer genomics and precision medicine, and pharmaceutical and therapeutic research.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sup1">
      <label>gkz917_Supplemental_Files</label>
      <media xlink:href="gkz917_supplemental_files.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>ACKNOWLEDGEMENTS</title>
    <p>We thank the members of the Center for Computational Systems Medicine (CCSM) for valuable discussion. We also thank Talissa Chapin for improving the English of the manuscript and web site.</p>
  </ack>
  <sec id="SEC6">
    <title>SUPPLEMENTARY DATA</title>
    <p><ext-link ext-link-type="uri" xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkz917#supplementary-data">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC7">
    <title>FUNDING</title>
    <p>National Institutes of Health (NIH) [R01GM123037, U01AR069395-01A1, R01CA241930 to X.Z.]; The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Funding for open access charge: Dr &amp; Mrs Carl V. Vartian Chair Professorship Funds to Dr Zhou from the University of Texas Health Science Center at Houston.</p>
    <p><italic>Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tazi</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Bakkour</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Stamm</surname><given-names>S.</given-names></name></person-group><article-title>Alternative splicing and disease</article-title>. <source>Biochim. Biophys. Acta</source>. <year>2009</year>; <volume>1792</volume>:<fpage>14</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">18992329</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Florea</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Salzberg</surname><given-names>S.L.</given-names></name></person-group><article-title>Thousands of exon skipping events differentiate among splicing patterns in sixteen human tissues [version 2; peer review: 2 approved]</article-title>. <source>F1000Research</source>. <year>2013</year>; <volume>2</volume>:<fpage>188</fpage>.<pub-id pub-id-type="pmid">24555089</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barny</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Perrault</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Michel</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Soussan</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Goudin</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Rio</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Attie-Bitach</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Hamel</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Dollfus</surname><given-names>H.</given-names></name><etal>et al</etal>.</person-group><article-title>Basal exon skipping and nonsense-associated altered splicing allows bypassing complete CEP290 loss-of-function in individuals with unusually mild retinal disease</article-title>. <source>Hum. Mol. Genet.</source><year>2018</year>; <volume>27</volume>:<fpage>2689</fpage>–<lpage>2702</lpage>.<pub-id pub-id-type="pmid">29771326</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Mishima</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Shima</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Akiyama</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Suzuki</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Suzuki</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Nakayama</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Takeshima</surname><given-names>Y.</given-names></name><etal>et al</etal>.</person-group><article-title>Exonic mutations in the SLC12A3 gene cause exon skipping and premature termination in Gitelman syndrome</article-title>. <source>J. Am. Soc. Nephrol.: JASN</source>. <year>2015</year>; <volume>26</volume>:<fpage>271</fpage>–<lpage>279</lpage>.<pub-id pub-id-type="pmid">25060058</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oda</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Sato</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Kunishima</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Nakagawa</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Izawa</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Hiejima</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Yasumi</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Doi</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Katamura</surname><given-names>K.</given-names></name><etal>et al</etal>.</person-group><article-title>Exon skipping causes atypical phenotypes associated with a loss-of-function mutation in FLNA by restoring its protein function</article-title>. <source>Eur. J. Hum. Genet.: EJHG</source>. <year>2016</year>; <volume>24</volume>:<fpage>408</fpage>–<lpage>414</lpage>.<pub-id pub-id-type="pmid">26059841</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>J.E.</given-names></name>, <name name-style="western"><surname>Byun</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Risacher</surname><given-names>S.L.</given-names></name>, <name name-style="western"><surname>Saykin</surname><given-names>A.J.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Nho</surname><given-names>K.</given-names></name><collab>for Alzheimer's Disease Neuroimaging, I.</collab></person-group><article-title>Identification of exon skipping events associated with Alzheimer's disease in the human hippocampus</article-title>. <source>BMC Med. Genet.</source><year>2019</year>; <volume>12</volume>:<fpage>13</fpage>.</mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramsbottom</surname><given-names>S.A.</given-names></name>, <name name-style="western"><surname>Molinari</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Srivastava</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Silberman</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Henry</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Alkanderi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Devlin</surname><given-names>L.A.</given-names></name>, <name name-style="western"><surname>White</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Steel</surname><given-names>D.H.</given-names></name>, <name name-style="western"><surname>Saunier</surname><given-names>S.</given-names></name><etal>et al</etal>.</person-group><article-title>Targeted exon skipping of a CEP290 mutation rescues Joubert syndrome phenotypes in vitro and in a murine model</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source><year>2018</year>; <volume>115</volume>:<fpage>12489</fpage>–<lpage>12494</lpage>.<pub-id pub-id-type="pmid">30446612</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niks</surname><given-names>E.H.</given-names></name>, <name name-style="western"><surname>Aartsma-Rus</surname><given-names>A.</given-names></name></person-group><article-title>Exon skipping: a first in class strategy for Duchenne muscular dystrophy</article-title>. <source>Expert Opin. Biol. Ther.</source><year>2017</year>; <volume>17</volume>:<fpage>225</fpage>–<lpage>236</lpage>.<pub-id pub-id-type="pmid">27936976</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awad</surname><given-names>M.M.</given-names></name>, <name name-style="western"><surname>Oxnard</surname><given-names>G.R.</given-names></name>, <name name-style="western"><surname>Jackman</surname><given-names>D.M.</given-names></name>, <name name-style="western"><surname>Savukoski</surname><given-names>D.O.</given-names></name>, <name name-style="western"><surname>Hall</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Shivdasani</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Heng</surname><given-names>J.C.</given-names></name>, <name name-style="western"><surname>Dahlberg</surname><given-names>S.E.</given-names></name>, <name name-style="western"><surname>Janne</surname><given-names>P.A.</given-names></name>, <name name-style="western"><surname>Verma</surname><given-names>S.</given-names></name><etal>et al</etal>.</person-group><article-title>MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression</article-title>. <source>J. Clin. Oncol.</source><year>2016</year>; <volume>34</volume>:<fpage>721</fpage>–<lpage>730</lpage>.<pub-id pub-id-type="pmid">26729443</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reungwetwattana</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Ou</surname><given-names>S.I.</given-names></name></person-group><article-title>The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable</article-title>. <source>Lung Cancer</source>. <year>2017</year>; <volume>103</volume>:<fpage>27</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">28024693</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aartsma-Rus</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>van Ommen</surname><given-names>G.J.</given-names></name></person-group><article-title>Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications</article-title>. <source>RNA</source>. <year>2007</year>; <volume>13</volume>:<fpage>1609</fpage>–<lpage>1624</lpage>.<pub-id pub-id-type="pmid">17684229</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kahles</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Lehmann</surname><given-names>K.V.</given-names></name>, <name name-style="western"><surname>Toussaint</surname><given-names>N.C.</given-names></name>, <name name-style="western"><surname>Huser</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Stark</surname><given-names>S.G.</given-names></name>, <name name-style="western"><surname>Sachsenberg</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Stegle</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Kohlbacher</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Sander</surname><given-names>C.</given-names></name><collab>Cancer Genome Atlas Research, N.</collab><etal>et al</etal>.</person-group><article-title>Comprehensive analysis of alternative splicing across tumors from 8,705 patients</article-title>. <source>Cancer Cell</source>. <year>2018</year>; <volume>34</volume>:<fpage>211</fpage>–<lpage>224</lpage>.<pub-id pub-id-type="pmid">30078747</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mele</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ferreira</surname><given-names>P.G.</given-names></name>, <name name-style="western"><surname>Reverter</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>DeLuca</surname><given-names>D.S.</given-names></name>, <name name-style="western"><surname>Monlong</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Sammeth</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>T.R.</given-names></name>, <name name-style="western"><surname>Goldmann</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Pervouchine</surname><given-names>D.D.</given-names></name>, <name name-style="western"><surname>Sullivan</surname><given-names>T.J.</given-names></name><etal>et al</etal>.</person-group><article-title>Human genomics. the human transcriptome across tissues and individuals</article-title>. <source>Science</source>. <year>2015</year>; <volume>348</volume>:<fpage>660</fpage>–<lpage>665</lpage>.<pub-id pub-id-type="pmid">25954002</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H.Y.</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>Z.G.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>R.Q.</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>X.H.</given-names></name>, <name name-style="western"><surname>Dang</surname><given-names>Y.W.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>S.L.</given-names></name></person-group><article-title>Prognostic index of aberrant mRNA splicing profiling acts as a predictive indicator for hepatocellular carcinoma based on TCGA SpliceSeq data</article-title>. <source>Int. J. Oncol.</source><year>2019</year>; <volume>55</volume>:<fpage>425</fpage>–<lpage>438</lpage>.<pub-id pub-id-type="pmid">31268164</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name></person-group><article-title>TSVdb: a web-tool for TCGA splicing variants analysis</article-title>. <source>BMC Genomics</source>. <year>2018</year>; <volume>19</volume>:<fpage>405</fpage>.<pub-id pub-id-type="pmid">29843604</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>J.E.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>Y.</given-names></name></person-group><article-title>CAS-viewer: web-based tool for splicing-guided integrative analysis of multi-omics cancer data</article-title>. <source>BMC Med. Genet.</source><year>2018</year>; <volume>11</volume>:<fpage>25</fpage>.</mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lev Maor</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Yearim</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Ast</surname><given-names>G.</given-names></name></person-group><article-title>The alternative role of DNA methylation in splicing regulation</article-title>. <source>Trends Genet.</source><year>2015</year>; <volume>31</volume>:<fpage>274</fpage>–<lpage>280</lpage>.<pub-id pub-id-type="pmid">25837375</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wishart</surname><given-names>D.S.</given-names></name>, <name name-style="western"><surname>Feunang</surname><given-names>Y.D.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>A.C.</given-names></name>, <name name-style="western"><surname>Lo</surname><given-names>E.J.</given-names></name>, <name name-style="western"><surname>Marcu</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Grant</surname><given-names>J.R.</given-names></name>, <name name-style="western"><surname>Sajed</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Sayeeda</surname><given-names>Z.</given-names></name><etal>et al</etal>.</person-group><article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinero</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Bravo</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Queralt-Rosinach</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Gutierrez-Sacristan</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Deu-Pons</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Centeno</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Garcia-Garcia</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Sanz</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Furlong</surname><given-names>L.I.</given-names></name></person-group><article-title>DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants</article-title>. <source>Nucleic Acids Res.</source><year>2017</year>; <volume>45</volume>:<fpage>D833</fpage>–<lpage>D839</lpage>.<pub-id pub-id-type="pmid">27924018</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frankish</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Diekhans</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ferreira</surname><given-names>A.M.</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Jungreis</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Loveland</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Mudge</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Sisu</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Wright</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Armstrong</surname><given-names>J.</given-names></name><etal>et al</etal>.</person-group><article-title>GENCODE reference annotation for the human and mouse genomes</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D766</fpage>–<lpage>D773</lpage>.<pub-id pub-id-type="pmid">30357393</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camacho</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Coulouris</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Avagyan</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Papadopoulos</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Bealer</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Madden</surname><given-names>T.L.</given-names></name></person-group><article-title>BLAST+: architecture and applications</article-title>. <source>BMC Bioinformatics</source>. <year>2009</year>; <volume>10</volume>:<fpage>421</fpage>.<pub-id pub-id-type="pmid">20003500</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>UniProt</surname><given-names>C.</given-names></name></person-group><article-title>UniProt: a worldwide hub of protein knowledge</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D506</fpage>–<lpage>D515</lpage>.<pub-id pub-id-type="pmid">30395287</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wimmer</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Roca</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Beiglbock</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Callens</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Etzler</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Rao</surname><given-names>A.R.</given-names></name>, <name name-style="western"><surname>Krainer</surname><given-names>A.R.</given-names></name>, <name name-style="western"><surname>Fonatsch</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Messiaen</surname><given-names>L.</given-names></name></person-group><article-title>Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5′ splice-site disruption</article-title>. <source>Hum. Mutat.</source><year>2007</year>; <volume>28</volume>:<fpage>599</fpage>–<lpage>612</lpage>.<pub-id pub-id-type="pmid">17311297</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anna</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Monika</surname><given-names>G.</given-names></name></person-group><article-title>Splicing mutations in human genetic disorders: examples, detection, and confirmation</article-title>. <source>J. Appl. Genet.</source><year>2018</year>; <volume>59</volume>:<fpage>253</fpage>–<lpage>268</lpage>.<pub-id pub-id-type="pmid">29680930</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.X.</given-names></name>, <name name-style="western"><surname>Cartegni</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>M.Q.</given-names></name>, <name name-style="western"><surname>Krainer</surname><given-names>A.R.</given-names></name></person-group><article-title>A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes</article-title>. <source>Nat. Genet.</source><year>2001</year>; <volume>27</volume>:<fpage>55</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">11137998</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Littink</surname><given-names>K.W.</given-names></name>, <name name-style="western"><surname>Pott</surname><given-names>J.W.</given-names></name>, <name name-style="western"><surname>Collin</surname><given-names>R.W.</given-names></name>, <name name-style="western"><surname>Kroes</surname><given-names>H.Y.</given-names></name>, <name name-style="western"><surname>Verheij</surname><given-names>J.B.</given-names></name>, <name name-style="western"><surname>Blokland</surname><given-names>E.A.</given-names></name>, <name name-style="western"><surname>de Castro Miro</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Hoyng</surname><given-names>C.B.</given-names></name>, <name name-style="western"><surname>Klaver</surname><given-names>C.C.</given-names></name>, <name name-style="western"><surname>Koenekoop</surname><given-names>R.K.</given-names></name><etal>et al</etal>.</person-group><article-title>A novel nonsense mutation in CEP290 induces exon skipping and leads to a relatively mild retinal phenotype</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source><year>2010</year>; <volume>51</volume>:<fpage>3646</fpage>–<lpage>3652</lpage>.<pub-id pub-id-type="pmid">20130272</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lalonde</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Stone</surname><given-names>O.A.</given-names></name>, <name name-style="western"><surname>Lessard</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Lavertu</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Desjardins</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Beaudoin</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Rivas</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Stainier</surname><given-names>D.Y.R.</given-names></name>, <name name-style="western"><surname>Lettre</surname><given-names>G.</given-names></name></person-group><article-title>Frameshift indels introduced by genome editing can lead to in-frame exon skipping</article-title>. <source>PLoS One</source>. <year>2017</year>; <volume>12</volume>:<fpage>e0178700</fpage>.<pub-id pub-id-type="pmid">28570605</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quinlan</surname><given-names>A.R.</given-names></name></person-group><article-title>BEDTools: The Swiss-Army Tool for Genome Feature Analysis</article-title>. <source>Curr. Protoc. Bioinformatics</source>. <year>2014</year>; <volume>47</volume>:<comment>doi:10.1002/0471250953.bi1112s47</comment>.</mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katz</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>E.T.</given-names></name>, <name name-style="western"><surname>Silterra</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Schwartz</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Thorvaldsdottir</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>J.T.</given-names></name>, <name name-style="western"><surname>Mesirov</surname><given-names>J.P.</given-names></name>, <name name-style="western"><surname>Airoldi</surname><given-names>E.M.</given-names></name>, <name name-style="western"><surname>Burge</surname><given-names>C.B.</given-names></name></person-group><article-title>Quantitative visualization of alternative exon expression from RNA-seq data</article-title>. <source>Bioinformatics</source>. <year>2015</year>; <volume>31</volume>:<fpage>2400</fpage>–<lpage>2402</lpage>.<pub-id pub-id-type="pmid">25617416</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shabalin</surname><given-names>A.A.</given-names></name></person-group><article-title>Matrix eQTL: ultra fast eQTL analysis via large matrix operations</article-title>. <source>Bioinformatics</source>. <year>2012</year>; <volume>28</volume>:<fpage>1353</fpage>–<lpage>1358</lpage>.<pub-id pub-id-type="pmid">22492648</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kent</surname><given-names>W.J.</given-names></name>, <name name-style="western"><surname>Sugnet</surname><given-names>C.W.</given-names></name>, <name name-style="western"><surname>Furey</surname><given-names>T.S.</given-names></name>, <name name-style="western"><surname>Roskin</surname><given-names>K.M.</given-names></name>, <name name-style="western"><surname>Pringle</surname><given-names>T.H.</given-names></name>, <name name-style="western"><surname>Zahler</surname><given-names>A.M.</given-names></name>, <name name-style="western"><surname>Haussler</surname><given-names>D.</given-names></name></person-group><article-title>The human genome browser at UCSC</article-title>. <source>Genome Res.</source><year>2002</year>; <volume>12</volume>:<fpage>996</fpage>–<lpage>1006</lpage>.<pub-id pub-id-type="pmid">12045153</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O’Leary</surname><given-names>N.A.</given-names></name>, <name name-style="western"><surname>Wright</surname><given-names>M.W.</given-names></name>, <name name-style="western"><surname>Brister</surname><given-names>J.R.</given-names></name>, <name name-style="western"><surname>Ciufo</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Haddad</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>McVeigh</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Rajput</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Robbertse</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Smith-White</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Ako-Adjei</surname><given-names>D.</given-names></name><etal>et al</etal>.</person-group><article-title>Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>D733</fpage>–<lpage>D745</lpage>.<pub-id pub-id-type="pmid">26553804</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zerbino</surname><given-names>D.R.</given-names></name>, <name name-style="western"><surname>Achuthan</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Akanni</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Amode</surname><given-names>M.R.</given-names></name>, <name name-style="western"><surname>Barrell</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Bhai</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Billis</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Cummins</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Gall</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Giron</surname><given-names>C.G.</given-names></name><etal>et al</etal>.</person-group><article-title>Ensembl 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D754</fpage>–<lpage>D761</lpage>.<pub-id pub-id-type="pmid">29155950</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sigrist</surname><given-names>C.J.</given-names></name>, <name name-style="western"><surname>de Castro</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Cerutti</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Cuche</surname><given-names>B.A.</given-names></name>, <name name-style="western"><surname>Hulo</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Bridge</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Bougueleret</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Xenarios</surname><given-names>I.</given-names></name></person-group><article-title>New and continuing developments at PROSITE</article-title>. <source>Nucleic Acids Res.</source><year>2013</year>; <volume>41</volume>:<fpage>D344</fpage>–<lpage>D347</lpage>.<pub-id pub-id-type="pmid">23161676</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subramanian</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Tamayo</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Mootha</surname><given-names>V.K.</given-names></name>, <name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Ebert</surname><given-names>B.L.</given-names></name>, <name name-style="western"><surname>Gillette</surname><given-names>M.A.</given-names></name>, <name name-style="western"><surname>Paulovich</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Pomeroy</surname><given-names>S.L.</given-names></name>, <name name-style="western"><surname>Golub</surname><given-names>T.R.</given-names></name>, <name name-style="western"><surname>Lander</surname><given-names>E.S.</given-names></name><etal>et al</etal>.</person-group><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source><year>2005</year>; <volume>102</volume>:<fpage>15545</fpage>–<lpage>15550</lpage>.<pub-id pub-id-type="pmid">16199517</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aoki</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Yokota</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Wood</surname><given-names>M.J.</given-names></name></person-group><article-title>Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy</article-title>. <source>BioMed. Res. Int.</source><year>2013</year>; <volume>2013</volume>:<fpage>402369</fpage>.<pub-id pub-id-type="pmid">23984357</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quax</surname><given-names>T.E.</given-names></name>, <name name-style="western"><surname>Claassens</surname><given-names>N.J.</given-names></name>, <name name-style="western"><surname>Soll</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>van der Oost</surname><given-names>J.</given-names></name></person-group><article-title>Codon bias as a means to fine-tune gene expression</article-title>. <source>Mol. Cell</source>. <year>2015</year>; <volume>59</volume>:<fpage>149</fpage>–<lpage>161</lpage>.<pub-id pub-id-type="pmid">26186290</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vetsigian</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Goldenfeld</surname><given-names>N.</given-names></name></person-group><article-title>Genome rhetoric and the emergence of compositional bias</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source><year>2009</year>; <volume>106</volume>:<fpage>215</fpage>–<lpage>220</lpage>.<pub-id pub-id-type="pmid">19116280</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajjari</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Khoshnevisan</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Behmanesh</surname><given-names>M.</given-names></name></person-group><article-title>Compositional features are potentially involved in the regulation of gene expression of tumor suppressor genes in human tissues</article-title>. <source>Gene</source>. <year>2014</year>; <volume>553</volume>:<fpage>126</fpage>–<lpage>129</lpage>.<pub-id pub-id-type="pmid">25303870</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sankaran</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Cavatorta</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Huskens</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Jonkheijm</surname><given-names>P.</given-names></name></person-group><article-title>Cell adhesion on RGD-displaying knottins with varying numbers of tryptophan amino acids to tune the affinity for assembly on Cucurbit[8]uril surfaces</article-title>. <source>Langmuir</source>. <year>2017</year>; <volume>33</volume>:<fpage>8813</fpage>–<lpage>8820</lpage>.<pub-id pub-id-type="pmid">28514856</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huettner</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Dargaville</surname><given-names>T.R.</given-names></name>, <name name-style="western"><surname>Forget</surname><given-names>A.</given-names></name></person-group><article-title>Discovering cell-adhesion peptides in tissue engineering: beyond RGD</article-title>. <source>Trends Biotechnol.</source><year>2018</year>; <volume>36</volume>:<fpage>372</fpage>–<lpage>383</lpage>.<pub-id pub-id-type="pmid">29422411</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harding</surname><given-names>S.D.</given-names></name>, <name name-style="western"><surname>Sharman</surname><given-names>J.L.</given-names></name>, <name name-style="western"><surname>Faccenda</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Southan</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Pawson</surname><given-names>A.J.</given-names></name>, <name name-style="western"><surname>Ireland</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Gray</surname><given-names>A.J.G.</given-names></name>, <name name-style="western"><surname>Bruce</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Alexander</surname><given-names>S.P.H.</given-names></name>, <name name-style="western"><surname>Anderton</surname><given-names>S.</given-names></name><etal>et al</etal>.</person-group><article-title>The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1091</fpage>–<lpage>D1106</lpage>.<pub-id pub-id-type="pmid">29149325</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>N.K.</given-names></name>, <name name-style="western"><surname>Wickens</surname><given-names>M.</given-names></name></person-group><article-title>Control of translation initiation in animals</article-title>. <source>Annu. Rev. Cell Dev. Biol.</source><year>1998</year>; <volume>14</volume>:<fpage>399</fpage>–<lpage>458</lpage>.<pub-id pub-id-type="pmid">9891789</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mignone</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Gissi</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Liuni</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Pesole</surname><given-names>G.</given-names></name></person-group><article-title>Untranslated regions of mRNAs</article-title>. <source>Genome Biol.</source><year>2002</year>; <volume>3</volume>:<comment>REVIEWS0004</comment>.</mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wickens</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>R.J.</given-names></name></person-group><article-title>Life and death in the cytoplasm: messages from the 3′ end</article-title>. <source>Curr. Opin. Genet. Dev.</source><year>1997</year>; <volume>7</volume>:<fpage>220</fpage>–<lpage>232</lpage>.<pub-id pub-id-type="pmid">9115434</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stelzer</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Rosen</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Plaschkes</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Zimmerman</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Twik</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Fishilevich</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Stein</surname><given-names>T.I.</given-names></name>, <name name-style="western"><surname>Nudel</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Lieder</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Mazor</surname><given-names>Y.</given-names></name><etal>et al</etal>.</person-group><article-title>The GeneCards suite: From gene data mining to disease genome sequence analyses</article-title>. <source>Curr. Protoc. Bioinformatics</source>. <year>2016</year>; <volume>54</volume>:<fpage>1.30.1</fpage>–<lpage>1.30.33</lpage>.<pub-id pub-id-type="pmid">27322403</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kreft</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Soete</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Hulpiau</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Botzki</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Saeys</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>De Bleser</surname><given-names>P.</given-names></name></person-group><article-title>ConTra v3: a tool to identify transcription factor binding sites across species, update 2017</article-title>. <source>Nucleic Acids Res.</source><year>2017</year>; <volume>45</volume>:<fpage>W490</fpage>–<lpage>W494</lpage>.<pub-id pub-id-type="pmid">28472390</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghandi</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>F.W.</given-names></name>, <name name-style="western"><surname>Jane-Valbuena</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Kryukov</surname><given-names>G.V.</given-names></name>, <name name-style="western"><surname>Lo</surname><given-names>C.C.</given-names></name>, <name name-style="western"><surname>McDonald</surname><given-names>E.R.</given-names><suffix>3rd</suffix></name>, <name name-style="western"><surname>Barretina</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Gelfand</surname><given-names>E.T.</given-names></name>, <name name-style="western"><surname>Bielski</surname><given-names>C.M.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><etal>et al</etal>.</person-group><article-title>Next-generation characterization of the Cancer Cell Line Encyclopedia</article-title>. <source>Nature</source>. <year>2019</year>; <volume>569</volume>:<fpage>503</fpage>–<lpage>508</lpage>.<pub-id pub-id-type="pmid">31068700</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Gurdziel</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Pique-Regi</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Ruden</surname><given-names>D.M.</given-names></name></person-group><article-title>Identification of Splicing Quantitative Trait Loci (sQTL) in Drosophila melanogaster with Developmental Lead (Pb(2+)) Exposure</article-title>. <source>Front. Genet.</source><year>2017</year>; <volume>8</volume>:<fpage>145</fpage>.<pub-id pub-id-type="pmid">29114259</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shukla</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kavak</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Gregory</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Imashimizu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Shutinoski</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Kashlev</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Oberdoerffer</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Sandberg</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Oberdoerffer</surname><given-names>S.</given-names></name></person-group><article-title>CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing</article-title>. <source>Nature</source>. <year>2011</year>; <volume>479</volume>:<fpage>74</fpage>–<lpage>79</lpage>.<pub-id pub-id-type="pmid">21964334</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>J.I.</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>E.P.</given-names></name>, <name name-style="western"><surname>Castle</surname><given-names>J.C.</given-names></name>, <name name-style="western"><surname>Crespo-Barreto</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Bowman</surname><given-names>A.B.</given-names></name>, <name name-style="western"><surname>Rose</surname><given-names>M.F.</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Richman</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Berget</surname><given-names>S.</given-names></name><etal>et al</etal>.</person-group><article-title>Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source><year>2005</year>; <volume>102</volume>:<fpage>17551</fpage>–<lpage>17558</lpage>.<pub-id pub-id-type="pmid">16251272</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piacentini</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Fanti</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Negri</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Del Vescovo</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Fatica</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Altieri</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Pimpinelli</surname><given-names>S.</given-names></name></person-group><article-title>Heterochromatin protein 1 (HP1a) positively regulates euchromatic gene expression through RNA transcript association and interaction with hnRNPs in Drosophila</article-title>. <source>PLos Genet.</source><year>2009</year>; <volume>5</volume>:<fpage>e1000670</fpage>.<pub-id pub-id-type="pmid">19798443</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schafer</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Miao</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Benson</surname><given-names>C.C.</given-names></name>, <name name-style="western"><surname>Heinig</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Cook</surname><given-names>S.A.</given-names></name>, <name name-style="western"><surname>Hubner</surname><given-names>N.</given-names></name></person-group><article-title>Alternative splicing signatures in RNA-seq data: percent spliced in (PSI)</article-title>. <source>Curr. Protoc. Hum. Genet.</source><year>2015</year>; <volume>87</volume>:<comment>doi:10.1002/0471142905.hg1116s87</comment>.</mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gronowitz</surname><given-names>J.S.</given-names></name>, <name name-style="western"><surname>Kallander</surname><given-names>C.F.</given-names></name>, <name name-style="western"><surname>Hagberg</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Persson</surname><given-names>L.</given-names></name></person-group><article-title>Deoxythymidine-kinase in cerebrospinal fluid: a new potential ‘marker’ for brain tumours</article-title>. <source>Acta Neurochir. (Wien)</source>. <year>1984</year>; <volume>73</volume>:<fpage>1</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">6093445</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
